Publication Name	World Journal of Hepatology
Manuscript ID	13536
Country	Türkiye

Received	2014-08-26 20:00
Peer-Review Started	2014-08-27 14:01
To Make the First Decision	2014-09-16 10:54
Return for Revision	2014-09-19 16:09
Revised	2014-10-31 14:59
Second Decision	2015-01-14 08:24
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-01-20 16:46
Articles in Press	2015-01-20 16:46
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-04-18 18:44
Publish the Manuscript Online	2015-05-01 19:01

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Lamivudine resistance in children with chronic hepatitis B
Manuscript Source	Invited Manuscript
All Author List	Erhun Kasırga
Funding Agency and Grant Number
Corresponding Author	Erhun Kasırga, Professor, Department of Pediatric Gastroenterology, Celal Bayar University, Uncubozköy Mh., Mimarsinan Bulv., No:173, 45030 Manisa, Turkey. hekasirga@hotmail.com
Key Words	Children; Chronic hepatitis B; Lamivudine; Lamivudine-resistant mutants; YMDD mutation
Core Tip	In present day, antiviral drugs with higher genotypic barrier to resistance cannot be used for children with chronic hepatitis B since these drugs are not covered by the general health insurance in many countries. Therefore, lamivudine (LAM) which is not used for adults due to its many drawbacks has been used as a first-line of treatment for children out of necessity. Even though long term treatment results with LAM appear to be good, long term treatment increases the possibility of occurrence of resistant strains. These strains which are resistant to LAM could develop cross resistance to other anti-viral agents.
Publish Date	2015-05-01 19:01
Citation	Kasırga E. Lamivudine resistance in children with chronic hepatitis B. World J Hepatol 2015; 7(6): 896-902
URL	http://www.wjgnet.com/1948-5182/full/v7/i6/896.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i6.896

Full Article (PDF)	WJH-7-896.pdf
Full Article (Word)	WJH-7-896.doc
Manuscript File	13536-Review.docx
Answering Reviewers	13536-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	13536-Conflict-of-interest statement.pdf
Copyright License Agreement	13536-Copyright assignment.pdf
Peer-review Report	13536-Peer review(s).pdf
Scientific Misconduct Check	13536-CrossCheck.jpg
Scientific Editor Work List	13536-Scientific editor work list.pdf